Abstract
Nucleobindin-2 mRNA level is down regulated in KRAS-mutation lung cancer cell lines compared with EGFR/BRAF/KRAS wild-type lung cancer cell lines
Highlights
Nucleobindin-2 mRNA Level is Down Regulated in KRASmutation Lung Cancer Cell Lines Compared with EGFR/ BRAF/KRAS Wild-type Lung Cancer Cell Lines
To the editor; Increased Nucleobindin-2 level has been determined as an independent prognostic factor for overall survival of patients [1,2]
We examined Nucleobindin-2 mRNA level in various types of human lung cancer cell lines
Summary
Nucleobindin-2 mRNA Level is Down Regulated in KRASmutation Lung Cancer Cell Lines Compared with EGFR/ BRAF/KRAS Wild-type Lung Cancer Cell Lines. Pathophysiological significance of Nucleobindin-2 in lung cancers remains unclear. We examined Nucleobindin-2 mRNA level in various types of human lung cancer cell lines. Ten of lung cancer cell lines with EGFR/BRAF/KRAS wildtype (H1299, H1819, HCC95, H838, H1437, H661, HCC15, HCC78, H1648, HCC193) and eleven of lung cancer cell lines with KRAS-mutation [KRAS-G12C (H2122, HCC44, H1792, HCC4017, H358), KRAS-G12V (H441), KRAS-G12D (HCC515), KRAS-G12R (H1264, H157), KRAS-G12A (H2009), KRAS-Q61H (H460)] were used [3].
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
